QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.

Press

28May 2024

Interested in how the Quantify team can help in meeting post-authorization commitments through Nordic RWE?

The Quantify Research team has years of experience of designing, supporting, and managing post-authorization studies, and has been a proud partner to the European Medicines Agency-coordinated ENCePP (European Network for Centres of Pharmacoepidemiology and Pharmacovigilance) initiative since 2020.

The Nordic data landscape is uniquely suited for studies on drug utilization, assessments of risk minimization measures, and long-term safety, due to several key factors:

𝐍𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐚𝐧𝐝 […]

25May 2024

Searching for that Friday feeling?

This week the Quantify Research team started early by going to Golfbaren Sverige for a round of mini golf on Thursday night. ⛳
The sun was shining and the competitive spirits ran high!
A big shout out to the winning team, number 3:
Helena Skröder Löveborn, Marcelina Kądziela and Hannah Norman
Well played you guys! ? ? ?

20May 2024

📢 𝐐𝐮𝐚𝐧𝐭𝐢𝐟𝐲 𝐩𝐮𝐛𝐥𝐢𝐬𝐡 𝐚 𝐭𝐚𝐫𝐠𝐞𝐭 𝐭𝐫𝐢𝐚𝐥 𝐞𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐆𝐔𝐓

Earlier this year, Quantify’s Emilie Toresson Grip co-authored a study in GUT, which aimed to emulate a target trial of GLP1 agonists’ effect on the risk of major adverse liver outcomes in patients with chronic liver disease and T2DM, using Swedish register data.

 

Target trial emulation constitutes an important conceptual framework for increasing the validity of causal inference in observational pharmacoepidemiologic research and is […]

15May 2024

Read Quantify´s publication assessing recent changes to adult national immunization programs for pneumococcal vaccination

In December 2023, Quantify’s Stuti Arya, Nicholas Norton and Puneet Kaushik published a study assessing recent changes to adult national immunization programs for pneumococcal vaccination and attempting to determine how those changes impacted coverage in European Adults. The review revealed evidence of a convergence towards immunization programs involving sequential vaccination with a higher-valency conjugate vaccine (PCV) followed by the polysaccharide vaccine (PPV23), with a common aim of reducing economic […]